Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03825484 |
Expanded Access Status :
Approved for marketing
First Posted : January 31, 2019
Last Update Posted : May 13, 2019
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Advanced Cancers and FGFR Genetic Alterations | Drug: Erdafitinib |
Study Type : | Expanded Access |
Expanded Access Type : | Intermediate-size Population |
See clinical trials of the intervention/treatment in this expanded access record. | |
Official Title: | Expanded Access Program (EAP) for Patients With Advanced Cancers and FGFR Genetic Alterations Who Have Exhausted All Treatment Options |
- Drug: Erdafitinib
Participants will start erdafitinib 8 milligram (mg) (formulated as tablets with 3 mg, 4 mg and 5 mg dosages) orally once daily until disease progression, intolerable toxicity, withdrawal of consent or decision by the doctor to discontinue treatment. Dose will be up-titrated to 9 mg based on serum phosphate levels and if there is no drug-related toxicity.Other Name: JNJ-42756493
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Participant has a documented fibroblast growth factor receptor (FGFR) alteration
- Participant does not have co-morbidities that would alter risk-benefit of providing erdafitinib (determined by treating physician's assessment)
- Life expectancy is greater than (>) 3 months (determined by treating physician's assessment)
- Participant has exhausted treatment options for their disease (review of prior treatments)
- Participant is not eligible for other erdafitinib clinical trials including but not limited to BLC3001/NCT03390504 and BLC2002/NCT03473743
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03825484
Study Director: | Janssen Scientific Affairs, LLC Clinical Trial | Janssen Scientific Affairs, LLC |
Responsible Party: | Janssen Scientific Affairs, LLC |
ClinicalTrials.gov Identifier: | NCT03825484 |
Other Study ID Numbers: |
CR108489 42756493MAF4001 ( Other Identifier: Janssen Scientific Affairs, LLC ) |
First Posted: | January 31, 2019 Key Record Dates |
Last Update Posted: | May 13, 2019 |
Last Verified: | May 2019 |
Neoplasms |